Tuesday, October 07, 2025
Expert.ai, a global leader in enterprise artificial intelligence solutions, has unveiled a new suite of AI-powered tools designed to accelerate innovation in the pharmaceutical, healthcare, and life sciences sectors. The announcement was made at BioTechX Europe 2025, the continent’s largest congress dedicated to advancements in pharma and healthcare technologies.
The new portfolio introduces four powerful solutions that aim to optimize research, documentation, and discovery across critical stages of life sciences operations.
EIX-Submission Readiness enables organizations to create smarter and more efficient workflows for regulatory documentation, ensuring accuracy and compliance.
EIX-Preclinical Document Intelligence automates preclinical documentation with enhanced precision and speed, allowing scientists and researchers to dedicate more time to innovation.
EIX-Clinical Trials Intelligence empowers research teams to extract accurate and up-to-date insights by analyzing vast datasets from clinical registries, publications, and real-world evidence.
EIX-IP Detection provides explainable and comprehensive insights across patents, clinical trial data, and scientific literature, supporting smarter intellectual property decisions.
With its hybrid AI approach and deep domain expertise, Expert.ai continues to transform the way organizations manage and interpret complex data. The company’s technology helps researchers turn the overwhelming complexity of research and development (R&D) into strategic value by automating data analysis, minimizing manual effort, and generating actionable insights at scale.
By integrating advanced natural language understanding and explainable AI, the new solutions not only ensure regulatory accuracy but also enhance trial design, improve patient recruitment, and reduce operational costs. Furthermore, they help mitigate the constant challenges of project delays that often hinder innovation in the life sciences sector.
“We're extremely proud of this new offering for Pharma & Life Sciences, which represents a significant advancement in our mission to harness AI for meaningful impact in these industries,” said Christophe Aubry, Global Head of Life Sciences & Healthcare at Expert.ai. “Our enhanced solutions are designed to reduce complexity, enhance scientific and regulatory accuracy, and free experts to focus on innovation where it matters most. By bringing automation, explainability, and traceability to every step—from research documentation to submission readiness—we enable smarter, faster, and compliant decision-making.”
Through these innovations, Expert.ai reinforces its leadership in the application of artificial intelligence for the life sciences domain. The company continues to redefine how data-driven decision-making can enhance efficiency, compliance, and reliability across the entire pharmaceutical value chain, setting a new standard for AI-driven document intelligence and automation in the industry.
Recommended News
To join our expert panel discussions, reach out to sudipto@intentamplify.com
Tags:
Coursera appoints Anthony Salcito as General Manager, Enterprise, starting October 6, 2025, to lead its global online learning platform’s enterprise division.
